Refik Pul

Carl Neuberg Str. 1
Hannover, NI 30625, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

Correction: Matched-pair analysis of motor outcomes in adults with spinal muscular atrophy on nusinersen vs. risdiplam.

Correction: Matched-pair analysis of motor outcomes in adults with spinal muscular atrophy on nusinersen vs. risdiplam.

Journal: Journal of neurology

Published: March 28, 2026

Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy.

Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy.

Journal: JAMA neurology

Published: January 20, 2026

Treatment-free remission in MS: long-term disease control with cladribine tablets.

Treatment-free remission in MS: long-term disease control with cladribine tablets.

Journal: Journal of neurology

Published: December 21, 2025

Matched-pair analysis of motor outcomes in adults with spinal muscular atrophy on nusinersen vs. risdiplam.

Matched-pair analysis of motor outcomes in adults with spinal muscular atrophy on nusinersen vs. risdiplam.

Journal: Journal of neurology

Published: November 03, 2025

Switching from anti-CD20 therapies to cladribine and vice versa - Analysis of a German relapsing multiple sclerosis cohort.

Switching from anti-CD20 therapies to cladribine and vice versa - Analysis of a German relapsing multiple sclerosis cohort.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: September 08, 2025

Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy.

Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy.

Journal: Journal of neurology

Published: September 05, 2025

The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study.

The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study.

Journal: Journal of neurology

Published: May 30, 2025

Kappa free light chain concentration in serum is reduced after CD20-depletion with ocrelizumab.

Kappa free light chain concentration in serum is reduced after CD20-depletion with ocrelizumab.

Journal: Neurological research and practice

Published: May 20, 2025

Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis.

Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis.

Journal: Neurological research and practice

Published: March 05, 2025

Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study.

Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study.

Journal: Multiple sclerosis and related disorders

Published: March 04, 2025

Glatiramer Acetate Modifies the Immune Profiles of Monocyte-Derived Dendritic Cells In Vitro Without Affecting Their Generation.

Glatiramer Acetate Modifies the Immune Profiles of Monocyte-Derived Dendritic Cells In Vitro Without Affecting Their Generation.

Journal: International journal of molecular sciences

Published: January 17, 2025

Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis.

Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: December 16, 2024

Showing 1-12 of 100

Last Updated: 09/26/2026